Analyst Note
| Rachel Elfman |CureVac is working to expand its pipeline by furthering its cancer vaccine capabilities. CureVac acquired Amsterdam-based Frame Cancer Therapeutics for EUR 32 million. Frame Cancer Therapeutics is a private company focused on identifying neoantigens across different cancer types. CureVac also established a partnership with Belgium-based myNEO to develop mRNA-based cancer vaccines using myNEO’s tumor antigen discovery platform. This acquisition and partnership help to enhance CureVac’s oncology capabilities, but it’s too soon to forecast the impact of these new platforms since they are in very early research and development phases.